SIMOVIL 20 MG

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Δραστική ουσία:

SIMVASTATIN 20 MG

Διαθέσιμο από:

MERCK SHARP & DOHME ISRAEL LTD

Φαρμακολογική κατηγορία (ATC):

C10AA01

Φαρμακοτεχνική μορφή:

TABLETS

Οδός χορήγησης:

PER OS

Κατασκευάζεται από:

MERCK SHARP & DOHME B.V, HOLLAND

Θεραπευτική ομάδα:

SIMVASTATIN

Θεραπευτικές ενδείξεις:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simovil is indicated to: Reduce the risk of total mortality by reducing coronary death; Reduce the risk of non-fatal myocardial infarction; Reduce the risk for undergoing myocardial revascularization procedures; Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simovil is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simovil therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglycerid

Ημερομηνία της άδειας:

2013-01-01